Publication: Statins & risk of Clostridium difficile infection: A meta-analysis
dc.contributor.author | Karn Wijarnpreecha | en_US |
dc.contributor.author | Panadeekarn Panjawatanan | en_US |
dc.contributor.author | Charat Thongprayoon | en_US |
dc.contributor.author | Patompong Ungprasert | en_US |
dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
dc.contributor.other | Mayo Clinic | en_US |
dc.contributor.other | Chiang Mai University | en_US |
dc.contributor.other | Bassett Medical Center | en_US |
dc.date.accessioned | 2020-01-27T07:38:02Z | |
dc.date.available | 2020-01-27T07:38:02Z | |
dc.date.issued | 2019-10-01 | en_US |
dc.description.abstract | © 2019 Indian Journal of Medical Research. Background & objectives: Clostridium difficile infection is one of the most common healthcare-associated infections worldwide. Recent epidemiologic studies have suggested that statin users may have a lower risk of C. difficile infection, although the results are inconsistent. This meta-analysis was conducted with the aim of summarizing all available data to assess the risk of C. difficile infection among statin users versus non-users. Methods: A literature review was performed using the MEDLINE and EMBASE databases from inception to October 2017. Cohort, case-control and cross-sectional studies that compared the risk of C. difficile infection among statin users versus non-users were included. Pooled odds ratio (OR) and 95 per cent confidence interval (CI) were calculated using a random-effect, generic inverse variance method. Results: Six case-control studies and two cross-sectional studies met the eligibility criteria and were included in this meta-analysis. The risk of C. difficile infection among statin users was significantly lower than non-users with the pooled OR of 0.74 (95% CI, 0.61-0.89). The statistical heterogeneity of this study was high (I[2]=90%). Interpretation & conclusions: This meta-analysis demonstrated a decreased risk of C. difficile infection among statin users versus non-users. Further studies are required to clarify the role of statins for prevention of C. difficile infection in clinical practice. | en_US |
dc.identifier.citation | Indian Journal of Medical Research. Vol.150, No.4 (2019), 359-364 | en_US |
dc.identifier.doi | 10.4103/ijmr.IJMR_1973_17 | en_US |
dc.identifier.issn | 09715916 | en_US |
dc.identifier.other | 2-s2.0-85075942372 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/50065 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075942372&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.title | Statins & risk of Clostridium difficile infection: A meta-analysis | en_US |
dc.type | Review | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075942372&origin=inward | en_US |